We Believe that no one should ever be blindsided by disease.

Aldo Carrascoso, MBA

Aldo is the Co-Founder and CEO of InterVenn. InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. He is also the Founder and COO/CTO of San Francisco based company, Veem. Veem uses the blockchain to replace the outdated SWIFT system and it is changing the way global payments are sent and received across the world, making the process much simpler, faster, more transparent and secure.

Prior to founding InterVenn and Veem, he was the Founder and CTO of Jukin Media – one of the world's largest User Generated Content (UGC) licensing platforms with over half a trillion views. Aldo is also an angel investor focusing on NOVEL AI/ML, healthtech, nextgen cleantech, and blockchain opportunities. He has an MBA in Entrepreneurship from Babson and is a graduate of the Ateneo De Manila University.

Erwin Estigarribia

Erwin is the COO of InterVenn, and he brings decades of executive leadership experience from global companies such as Chiron, Novartis, Geron, Nugen, CardioDX and Applied Proteomics.

Erwin’s aspiration about cancer and other life ending diseases is to detect early and change the conversation from “this drug saved my life” to “this test saved my life”. He believes these diseases should be viewed as manageable conditions and not a painful losing battle. He holds a bachelor's degree in Chemical and Bioprocessing Engineering (with honors) from Swinburne University of Technology, Melbourne Australia.

Klaus Lindpaintner, M.D., MPH

Klaus guides preclinical and experimental research and clinical development at InterVenn. After serving on the faculty at Harvard University, he joined industry, working in executive positions at Roche, Pfizer, and Thermo Fisher Scientific, with a focus on the field of personalized health care.

He holds degrees in medicine and public health, is a board-certified internist, cardiologist, and medical geneticist, and an elected Fellow of the American Colleges of Physicians, Cardiology, and Medical Genetics. He has co-authored some 250 publications, with basic research interests in population and epidemiological genetics. Klaus is fascinated by the potential of InterVenn’s platform to contribute to a broad spectrum of health care needs, with a current focus on cancer.

Stephana Patton, Ph.D., J.D.

Stephana Patton brings 20 years of experience creating portfolio value at publicly-traded biotechnology and pharmaceutical companies. She joined us in April 2021. She was formerly the General Counsel, Corporate Secretary, and Chief Compliance Officer of Eiger BioPharmaceuticals, Inc., a commercial stage biopharmaceutical company focused on developing therapies for rare and ultra-rare diseases. Prior to Eiger, she was the General Counsel, Corporate Secretary, and Chief Compliance Officer of BioTime, Inc., a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases.

Prior to BioTime, she was the General Counsel and Commercial Compliance Officer at BioDelivery Sciences (BDSI), a publicly traded specialty pharmaceutical company. Before BDSI, she held various senior management positions, including leading Intellectual Property (IP) and Licensing at Salix Pharmaceuticals, a global pharmaceutical company that was acquired for $11.2 billion in 2015. Prior to joining Salix, Dr. Patton was in private practice at a large international law firm known for its IP and corporate securities practices. Her practice focused on counseling clients on IP-related matters as well as licensing transactions for biotechnology and pharmaceutical companies at varying stages of product development. Dr. Patton earned a J.D. from the Boston University School of Law, and a Ph.D. in Biochemistry, Cell, and Developmental Biology from Emory University.

Stephana decided at a young age that she would cure cancer and announced it at a school event. In a video of the event you hear people laughing in the background at the audacity and impossibility of the goal. While her path to meeting this goal has not always been evident to others, she is excited to be a part of the InterVenn family and contributing to the goal of ensuring that no one is blindsided by disease by employing novel technology to detect disease earlier, and thereby enabling better treatment choices.

John Leite, Ph.D.

John has spent the bulk of his career in new diagnostic technology development and commercialization. He has held several leadership roles in corporate strategy and development, business development, product marketing and commercialization. Most recently, John was VP, Clinical Business Development at Illumina cultivating pharma and IVD partnerships, as well as VP, Commercial Strategy for oncology diagnostics at Novartis.

John began his career as a biochemist with degrees from Rutgers University, University of Pittsburgh and was a National Research Service Award Fellow at the California Institute of Technology. John’s primary drive is to accelerate the deployment of tools to the clinic that significantly, efficiently improve patient outcomes.

Randolph Barr

Randolph brings over 20 years of information technology and leadership experience to the company. He was most recently Head of Security Operations at Zoom Video Communications (NASDAQ:ZM) where he was responsible for the aggressive growth of the overall security program on the Zoom platform.

Previously, Randolph was Chief Security Officer at CISCO – WEBEX Communications Senior Vice President and Chief Information and Security Officer at Topia and Senior Vice President and Chief Information Security Officer at Aryaka. He held several leadership positions at leading cloud companies ahead of this. Randolph earned a Bachelor of Administration and Computer Science from the University of Phoenix.

Katherine Dalao

Katherine is a Quality and Regulatory leader with over 21 years of experience in life science and medical device industry including commercialization of in-vitro diagnostic products in full compliance to FDA QSR, ISO 13485, ISO 15189 and other Regulatory Body standards for Clinical Lab operations as well as commercialization of FDA-cleared medical devices.

Prior to joining InterVenn, Katherine was Director of Quality and Operations at Spirosure. She was a member of the executive committee and was responsible for leading the Quality, Device Manufacturing Operations, Shipping, and Receiving groups. Katherine held several positions in Quality and Operations at Applied Proteomics, Verinata Health (now Illumina), NugenTechnologies (now Tecan), Ascend Genomics, CellScape, and Clontech (now Takara Bio). She holds a bachelor's degree in Molecular and Cellular Biology from San Diego State University. Cancer does not discriminate; anyone can be affected, and some are luckier than others in terms of surviving this horrible disease. She would like to be a part of a company that provides, if not a cure, another option for people battling this disease to survive, thrive and have more time to fulfill their purpose in life.

Dan Serie, M.S.

Daniel Serie is the Vice President of Bioinformatics and Data Science at InterVenn, with over 15 years of experience mining the genome and proteome for biological and clinical insights. After joining in late 2017, his team was responsible for training, deploying, and publishing the world's first neural network for mass spectrometry peak selection and integration.

Prior to starting at InterVenn, Daniel led analytical efforts for dozens of scientific publications in cancer, neurodegenerative disease, and cardiovascular health at the Mayo Clinic. He holds a Bachelor of Science degree in Mathematics from the University of Minnesota and a Master's in Applied Statistics from Penn State. His team continues development on advanced machine learning techniques for detecting, quantifying, and utilizing glycoproteins, in service of the ultimate goal: moving these novel biomarkers into clinical practice and improving patient outcomes.

Kaitlynn Moser

Kaitlynn serves InterVenn by supporting InterVenn's global clinical studies/trials as well as institutional collaborations through the department of Clinical Development. Before joining InterVenn, Kaitlynn spent over 10 years in academic and clinical research at the Mayo Clinic where she held multiple positions.

At the end of her tenure, Kaitlynn was responsible for developing strategic initiatives for efficiently initiating and optimizing the execution of clinical trials. Kaitlynn holds a B.S. in Biology, is certified as a Clinical Research Professional, and is currently pursuing a Master of Business Administration.

Ada Wong, M.S., J.D.

Ada’s mission at InterVenn is to develop the global intellectual property strategy for our products and platform technology and adapt it to meet the needs of our rapidly growing company. Having served in-house and in private practice, Ms. Wong has over 16 years of experience providing IP counseling and managing portfolios at different stages of the product development continuum. Prior to joining us in June of 2021, Ada was the Senior IP Counsel at Jazz Pharmaceuticals, where she devised and implemented global IP strategy for marketed drugs and clinical-phase products in the oncology and neuroscience space and spearheaded IP diligence for complex transactions. Before assuming her position at Jazz, Ms. Wong was a Senior Patent Counsel at Johnson & Johnson, where she supported the Infectious Disease therapeutic area, Computational Science and Emerging Science groups, and led IP diligence on multiple deals valued in the billion to hundred million dollar range.

Previously, she was a member of the IP and Licensing team at Salix Pharmaceuticals, where she actively engaged in prosecution to protect a diverse product lineup. Early in her career, Ms. Wong devoted 9 years to private practice at Morgan Lewis, specializing in patent prosecution and counseling clients in the biotech and pharmaceutical industries. Ada has a J.D. from Santa Clara University, an M.S. in Biotechnology with an emphasis in Bioinformatics from Johns Hopkins University, and a B.S. in Molecular Cell Biology from U.C. Berkeley. A firm believer in personalized healthcare, Ms. Wong is passionate in her commitment to protect the innovation that makes early detection possible.

Xin Cong, Ph.D.

Xin brings in expertise in LC-MS-based analytical method development and validation, and has extensive hands-on experience with clinical mass spectrometry. She holds a Ph.D in Analytical Chemistry from UC Davis. She brings to InterVenn extensive experience in assay development and workflow analysis involving mass spectrometry. Xin has advanced the research and development at Thermo Fisher Scientific, FitBit, Proctor and Gamble.

She has co-authored 17 publications and led several global presentations, primarily with a focus on mass-spectrometry. Xin’s mission here at InterVenn, is to spearhead innovation in LC-MS assays for glycoproteins and to oversee the mass spectrometry method architecture and implementation plans.

Axel Kornerup, MPA

Axel is an entrepreneur and a leader. He has founded five companies, all of which have become market leaders. He is experienced in managing business development, strategy, competitive analysis, and expansion for a variety of local and international companies and has developed management frameworks that drive concentration balancing between customers and shareholders.

He holds a master's degree in Public Administration and bachelor's degree in Marketing Management. Axel builds highly effective teams to synergize technology operations, sales, distribution, and marketing. His mission here at InterVenn is to apply innovation to solve relevant problems.

Fadzhari Jabar

Fadzhairi graduated from Creighton University, Omaha USA with a B.S. in Business Administration. He was a corporate banker by training, specialized in Project Financing, fund raising, Merger & Acquisition and Business Restructuring. In addition, Fadzhairi is also an experienced manager and entrepreneur with strong skills in Life Sciences, Deep Tech, Business Development, Finance, Project Management and Operations. Throughout 25 years of his career, Fadzhairi developed his career with the Malaysia corporate companies, Government companies and Ministries, with the last 15 years as the key management team, both in Malaysia and overseas. In addition, he is also the Vice President of the world’s largest not-for-profit pharmaceutical engineering society, International Society for Pharmaceutical Engineering (ISPE), Malaysia affiliate.

As one of the pioneers at InterVenn, Fadzhairi shares the belief that nobody should be blindsided by disease. The tools and data developed by InterVenn inspired him for a mission towards a healthier world. Hence, he shares InterVenn’s mission to Malaysia and to South East Asia by providing opportunities for the talents and the healthcare practitioners to benefit from the platform. Under Fadzhairi’s leadership together with the Malaysian team, they aspire to move boldly to advance the Cancer’s research and treatment to the Asian region. The focus is on the Asian’s prevalence of cancers such as Nasopharyngeal Carcinoma (NPC), Breast and Ovarian, Colorectal and others.